Chronic Obstructive Pulmonary Disease and Pain Management
This activity took place on May 6, 2012 in St. Petersburg, FL. You must attend the live event and provide a unique access code to receive credit for this activity.
Speakers:
Thomas C. Snader, PharmD, CGP, FASCP
Independent Consultant Pharmacist
Deans Professor of Clinical Pharmacy, University of the Sciences in Philadelphia
Sharon F. Clackum, PharmD, CGP, CDM
Senior Consultant & Pharmacotherapy Specialist
Visante Inc.
Faculty Disclosure:
Dr. Clackum has no actual or potential conflict of interest associated with this presentation.
Dr. Snader discloses the following: speaker and received honorarium from Boehringer Ingelheim, Mylan Labs, and Novartis Pharmaceuticals.
Learning Objectives:
At the conclusion of this application-based activity, participants will be able to:
- Define the financial and human health burden of asthma and chronic obstructive pulmonary disease (COPD) on the U.S. health care system with a focus on individuals with unmet needs.
- Outline evidence-based treatment plans for asthma and COPD that are consistent with current guidelines.
- Discuss comparative safety and efficacy data on currently available treatment options.
- Educate patients about treatment guidelines and adherence to medication therapy.
- Describe examples of how pharmacists and other health professionals can use evidence-based solutions to affect patient outcomes.
- Cite statistics related to chronic pain and opioid use, misuse, and abuse.
- Assess if a patient is an appropriate candidate for chronic opioid therapy for nonmalignant pain.
- Describe the importance of functional treatment goals for patients with chronic nonmalignant pain.
- Asses the impact of chronic opioid therapy in patients with chronic nonmalignant pain.
- Develop a strategy for managing a patient whose function declines while receiving chronic opioid therapy for nonmalignant pain.
Continuing Pharmacy Education
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity (UAN: 0203-9999-12-078-L01-P) is approved for 3.0 contact hours.
0